CGTX

COGNITION THERAPEUTICS INC

• Benzinga·1d ago

  Cognition Therapeutics To Update On Progress Of Its Development Programs For Alzheimer's Disease And Dementia With Lewy Bodies At 25th Annual Needham Virtual Healthcare Conference

• Reuters·1d ago

  Cognition Therapeutics CEO presents at Needham Virtual Healthcare Conference, updates Alzheimer’s, DLB programs

• Benzinga·04/01 17:06

  12 Health Care Stocks Moving In Wednesday's Intraday Session

• Reuters·03/31 20:41

  Cognition Therapeutics announces availability of CEO shareholder letter

• NASDAQ·03/31 16:01

  Tuesday Sector Leaders: Precious Metals, Drugs

• Benzinga·03/27 17:05

  12 Health Care Stocks Moving In Friday's Intraday Session

• Dow Jones·03/27 12:11

  Cognition Therapeutics Price Target Maintained With a $4.00/Share by Chardan Capital

• Dow Jones·03/27 12:11

  Cognition Therapeutics Is Maintained at Buy by Chardan Capital

• TipRanks·03/27 10:35

  Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications

• TipRanks·03/26 12:13

  Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress

• Reuters·03/26 11:39

  Cognition Therapeutics 2025 net loss narrows as expenses fall

• Seeking Alpha·03/26 11:34

  Cognition Therapeutics GAAP EPS of -$0.32 beats by $0.07

• Reuters·03/26 11:31

  Cognition Therapeutics FY2025 net loss per share narrows 62.79% to $(0.32); cash climbs 47.96% to $37.0 million

• Dow Jones·03/26 11:31

  *Cognition Therapeutics: Sufficient Cash to Fund Operations, Capital Spending Through 2Q 2027 >CGTX

• Reuters·03/26 11:30

  COGNITION THERAPEUTICS REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES CLINICAL DEVELOPMENT UPDATE